The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Small but mighty: Platelets in NASH and other chronic liver diseases
Hilscher MB1, Shah VH1. Hepatology. 2020 Jan 5. doi: 10.1002/hep.31101. [Epub ahead of print]
Author information
1 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Abstract
Recent studies have identified several pleiotropic effects of platelets on liver homeostasis and disease distinct from their long-recognized roles in hemostasis and coagulation. Concerns for bleeding have traditionally limited the use of anti-platelet agents in advanced liver disease. However, recent evidence increasingly suggests that pro-thrombotic tendencies may exceed the bleeding diathesis traditionally associated with advanced liver disease. This implies that anti-platelet therapy (APT) may in fact be safely used in certain patients with chronic liver disease.